CEL-SCI announces IDMC recommendation for Phase 3 Multikine study
CEL-SCI announced that the Independent Data Monitoring Committee, or IDMC, for the company's Phase 3 head and neck cancer study of its investigational immunotherapy Multikine has completed its recent review of the Phase 3 study data. The IDMC meets periodically to review the safety and efficacy of the ongoing Phase 3 study. The data from all 928 enrolled patients were provided to the IDMC by the clinical research organization responsible for data management of this Phase 3 study. At the most recent IDMC meeting in October the IDMC reviewed "progression free and overall survival and limited demographic and safety data available for the aforementioned protocol." The IDMC recommendation "is to continue the trial until the appropriate number of events has occurred".